Community Bank N.A. Has $2.07 Million Holdings in Pfizer Inc. (NYSE:PFE)

Community Bank N.A. decreased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 26.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 77,952 shares of the biopharmaceutical company's stock after selling 28,164 shares during the quarter. Community Bank N.A.'s holdings in Pfizer were worth $2,067,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the fourth quarter valued at $28,000. Noble Wealth Management PBC acquired a new position in Pfizer in the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer in the fourth quarter valued at about $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company's stock.

Remove Ads

Pfizer Stock Performance

NYSE:PFE traded down $0.36 during mid-day trading on Wednesday, reaching $25.19. 49,455,223 shares of the company's stock were exchanged, compared to its average volume of 36,731,923. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $142.88 billion, a PE ratio of 17.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The business's fifty day simple moving average is $26.14 and its two-hundred day simple moving average is $27.00. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the firm earned $0.10 EPS. The business's quarterly revenue was up 24.7% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Bank of America reaffirmed a "neutral" rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.